It features seven core manufacturing shops and over 30 production lines, warehouses for raw and direct materials as well as end products, quality control laboratories for raw materials and end products, research labs, and support functions.
One of the key employers in Kurgan.
The plant was founded in 1958.
Binnopharm makes innovative combination medications, biosimilars of fully authentic and biotechnological medicines of various therapeutic groups, such as pulmonology, neurology, cardiology, gastroenterology, and endocrinology. In 2020, the Binnopharm plant became the first facility in the world to produce Gam-COVID-Vac (Sputnik V), a COVID-19 vaccine.
The plant was founded in 2006.
It has an annual design capacity of 30 million plastic bottles of infusion solutions.
The site was commissioned in July 2010.
Alium was founded in 1994.
Biocom was founded in 1991.
Binnopharm Group constantly develops new pharmaceuticals and expands its portfolio.
Binnopharm Group began the construction of a single R&D centre in the Krasnogorsk District, Moscow Region, with a total floor area of 12,000 sq m.
Two research divisions:
Centre for Pharmaceutical Development of Chemically Synthesised Medicines (to be launched in Q1 2022)
- Centre for the Development of Biotechnological Medicines
By 2025, Binnopharm Group is set to market over 100 medical products for such disease areas as dermatology, neurology, gynaecology, paediatrics, etc.
Binnopharm Group makes high-quality, effective and safe medical products using state-of-the-art equipment and adhering to global standards of quality.
Taken together, laboratories at quality control (QC) departments have 400 employees who are responsible for the quality of our medicines. QC experts have the necessary educational background, qualifications, technical skills and experience to perform incoming inspections of raw materials, in-process controls and finished-product testing.
QC departments’ laboratories have cutting-edge equipment and include a unique pharmacology lab and an animal research facility.
Binnopharm Group’s production facilities have Good Manufacturing Practice (GMP) certificates from the Russian Ministry of Industry and Trade.
Continuous improvement of manufacturing processes and
implementation of the latest EAEU GMP requirements.
Adherence to GMP
Adherence to the industry-specific GMP requirements imposed on the processes
of product development manufacturing, and quality control
Every employee is involved in ensuring
the high quality of products
Quality and safety
Manufacturing of medical products that are fully compliant
with the applicable quality and safety requirements